Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference
February 18, 2025 09:15 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer
February 13, 2025 08:30 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
February 13, 2025 08:00 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and...
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology
January 28, 2025 09:05 ET
|
Sonnet BioTherapeutics Holdings, Inc.
European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) domain fusion proteins In addition to the U.S. and EU, Sonnet’s global IP...
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
January 22, 2025 08:35 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Live webcast on Wednesday, January 29th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a...
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
January 21, 2025 09:05 ET
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis®) with...
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment
December 23, 2024 09:20 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
December 17, 2024 08:50 ET
|
Sonnet BioTherapeutics Holdings, Inc.
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2...
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
December 09, 2024 15:42 ET
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
December 09, 2024 08:45 ET
|
Sonnet BioTherapeutics Holdings, Inc.
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months...